REHOVOT, ISRAEL--(Marketwire - June 02, 2009) -
| Highlighted Links |
|
Evogene Ltd. (TASE: EVGN) announced today that it has received $9 million from the exercise of the company’s series 1 options (expiration date May 31, 2009). The options were issued in June 2007 as part of the company’s initial public offering on the Tel Aviv Stock Exchange.
Ofer Haviv, Evogene’s president and CEO, stated: “We welcome this vote of confidence of our investors in the company with the exercise of 99.6% of the issued series 1 options.”
About Evogene
Evogene is a world leading developer of improved plant traits. The company’s proprietary product development platform combines state of the art computational gene discovery technology (The ‘ATHLETE’), plant and field validation capabilities and unique selection systems. Evogene’s current programs focus on the improvement of key plant traits, such as yield and stress tolerance, and the improvement of plants specifically for biofuel uses. Evogene has collaboration and licensing agreements with world leading companies in the agro-biotech and alternative energy industries. Evogene’s headquarters are in Rehovot, Israel, and its stock is traded on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene’s website at www.evogene.com.
This press release contains “forward-looking statements.” These statements include words like “may,” “expects,” “believes,” “scheduled” and “intends,” and they describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Evogene Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Contact Information
Evogene:
Liat Cinamon
PR & IR Executive
E-mail: Email Contact
Tel: +972-8-931-1933
